Compare FRMI & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMI | LGND |
|---|---|---|
| Founded | 2025 | 1987 |
| Country | United States | United States |
| Employees | 35 | 68 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | FRMI | LGND |
|---|---|---|
| Price | $8.55 | $263.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $26.13 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 16.4M | 172.7K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | $120.76 | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.47 | $111.72 |
| 52 Week High | $32.39 | $259.03 |
| Indicator | FRMI | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 72.04 | 75.66 |
| Support Level | $8.65 | $199.97 |
| Resistance Level | $10.57 | N/A |
| Average True Range (ATR) | 0.67 | 7.59 |
| MACD | 0.22 | 2.31 |
| Stochastic Oscillator | 86.59 | 90.88 |
Fermi Inc building a private power campus for AI-centric customers, developing and leasing large-scale, grid-independent energy generation and high-performance computing facilities purpose-built for the hyperscale era. The company is also developing a private energy and site infrastructure platform across the campus to support multiple powered shell buildings and a diversified, integrated power supply, including private power generation and delivery infrastructure, substations, internal distribution networks, water and cooling systems, and other essential infrastructure. In addition to powered shell facilities, it may offer long-term ground leases to tenants that elect to construct their own powered shell facilities on land, with or without integrated power delivery.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.